drugset / Trial / NCT02568306

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

NCT02568306

Phase 1 Completed 93 enrolled Novo Nordisk A/S
RandomizedSingle-groupDouble-blindTreatment

Summary

This trial is conducted in the United States of America. The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses and multiple doses of NNC0165-1562 in overweight to obese but otherwise healthy subjects.

Timeline

Start
2015-10-05
Primary completion
2017-02-07
Completion
2017-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0165-1562 Unknown Subcutaneous